OptimizeRx Corp. (OPRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$7.87-1.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
OptimizeRx aims to grow revenue to about $111.5 million in 2026. The company targets adjusted EBITDA near $23 million. It has announced share buybacks and seeks to improve cash flow. The valuation is cheap with a PE of 7.23 versus peers at 28.38.
Revenue growth is slow with only 1% expected next year. Cash from operations declined sharply to negative $467,000 in Q1 2026. Management changes and missed earnings raise concerns. The company remains loss-making and volatile.
The market prices in about 1% revenue growth and a fair value near $9, about 30% below current price. Our fair value is 14% below the Street median, reflecting cautious optimism. We see limited upside unless cash flow and growth improve.
Breaks if: adjusted EBITDA falls below $21 million in FY26
Breaks if: cash from operations remains negative or worsens over next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround play in the healthcare sector. OPRX is currently navigating a challenging environment with recent revenue declines but shows potential for recovery through management's focus on growth and debt reduction.
The market appears to have priced in a justified valuation, reflecting a premium compared to peers. However, there is an expectations gap, indicating that some investors may be cautious about future performance.
Management is focused on achieving revenue and adjusted EBITDA guidance despite recent declines. While the near-term risk of missing targets is low, the company has a history of volatility, which could impact future performance.
The thesis hinges on management's ability to meet revenue and EBITDA targets, as well as external factors like sector performance and economic conditions. Key indicators include guidance from sector bellwethers and overall job market health.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the revenue guidance for 2026. However, there are revenue headwinds that challenge achieving the same guidance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $109 million in FY26
In the next 1 to 3 years, OPRX's performance will depend on effective execution of management priorities and external market conditions. Not investment advice.